News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Radius to Present at Cowen and Company 33rd Annual Health Care Conference in Boston


2/27/2013 10:02:11 AM

CAMBRIDGE, MA--(Marketwire - February 26, 2013) -

Radius Health, Inc. ("Radius"), a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women's health conditions, announced today that it will present at the 33rd annual Cowen & Company Health Care Conference. Michael Wyzga, President and CEO of Radius Health, is scheduled to present on Monday, March 4, at 3:30 p.m. (EST). A breakout session follows the presentation. Senior Vice President and Chief Financial Officer Nick Harvey and Chief Medical Officer Louis Brenner, MD, will also be in attendance.

Radius will provide an update on the company and its Phase 3 asset, BA058, a novel anabolic, bone-building compound under development as a potential treatment for postmenopausal women with osteoporosis at high risk for fracture. BA058-SC, an injectable form of BA058, is currently in a Phase 3 trial, and BA058-TD, is in a Phase 2 trial studying the efficacy of delivering BA058 via transdermal patch. Radius and 3M Drug Delivery Systems have an exclusive partnership agreement for development and commercialization of BA058-TD.

Event
Cowen & Company Health Care Conference
Date
Monday, March 4
Time
3:30 p.m. EST
Place
Boston Marriott Copley Place
Vineyard Room, 4th Floor
110 Huntington Avenue
Boston, MA 02116

About Radius Health
Radius is a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women's health conditions. Radius is committed to the development of advanced therapeutics for the large and underserved osteoporosis market. The Company's lead product candidate, BA058-SC, is in development to reduce the risk of complications associated with osteoporosis, such as fracture. The company also has a next-generation transdermal patch, BA058-TD, being developed as a short wear-time delivery vehicle intended to improve patient compliance with convenience and ease of use, as well as a product in development to treat symptoms associated with menopause. Learn more by visiting the company's new website at www.RadiusPharm.com


CONTACTS:

Media:
Dave Connolly
617-374-8800
dconnolly@lavoiegroup.com

Investors:
Stacey Falardeau
617-374-8800
sfalardeau@lavoiegroup.com


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES